X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
infectious diseases (79) 79
humans (76) 76
tenofovir/emtricitabine (75) 75
index medicus (71) 71
hiv infections - drug therapy (54) 54
male (53) 53
female (50) 50
adult (48) 48
hiv (47) 47
tenofovir (47) 47
immunology (46) 46
emtricitabine (43) 43
antiretroviral therapy (39) 39
middle aged (38) 38
anti-hiv agents - therapeutic use (35) 35
human immunodeficiency virus--hiv (34) 34
tenofovir-emtricitabine (27) 27
treatment outcome (27) 27
hiv-infected patients (26) 26
safety (25) 25
efavirenz (24) 24
therapy (24) 24
adenine - analogs & derivatives (23) 23
anti-hiv agents - adverse effects (22) 22
antiretroviral drugs (22) 22
adults (21) 21
aids/hiv (21) 21
microbiology (21) 21
virology (21) 21
abacavir-lamivudine (20) 20
abacavir/lamivudine (20) 20
deoxycytidine - analogs & derivatives (20) 20
abacavir (19) 19
clinical trials (19) 19
raltegravir (19) 19
aids (18) 18
drug therapy (18) 18
efficacy (18) 18
viral load (18) 18
acquired immune deficiency syndrome--aids (17) 17
anti-hiv agents - administration & dosage (17) 17
antiviral agents (17) 17
hiv infection (17) 17
lamivudine (17) 17
hiv-1 (16) 16
pharmacology & pharmacy (16) 16
antiretroviral therapy, highly active - methods (15) 15
double-blind (15) 15
human immunodeficiency virus (14) 14
antiretroviral agents (13) 13
drug therapy, combination (13) 13
hiv-infection (13) 13
myocardial-infarction (13) 13
patients (12) 12
research article (12) 12
trial (12) 12
adenine - administration & dosage (11) 11
adenine - therapeutic use (11) 11
cd4 lymphocyte count (11) 11
deoxycytidine - administration & dosage (11) 11
drug combinations (11) 11
hiv infections - prevention & control (11) 11
hiv infections - virology (11) 11
hiv-1-infected patients (11) 11
organophosphonates - administration & dosage (11) 11
pre-exposure prophylaxis (11) 11
reverse-transcriptase inhibitors (11) 11
biomarkers (10) 10
deoxycytidine - therapeutic use (10) 10
disoproxil fumarate (10) 10
organophosphonates - therapeutic use (10) 10
prep (10) 10
protease inhibitors (10) 10
raltegravir potassium (10) 10
ritonavir (10) 10
acquired immune deficiency syndrome (9) 9
dideoxynucleosides - therapeutic use (9) 9
highly active antiretroviral therapy (9) 9
hiv prevention (9) 9
infection (9) 9
lamivudine - therapeutic use (9) 9
men (9) 9
open-label (9) 9
retrospective studies (9) 9
adenine - adverse effects (8) 8
antiretroviral therapy, highly active - adverse effects (8) 8
antiretroviral-naive (8) 8
antiretrovirals (8) 8
bone mineral density (8) 8
dideoxynucleosides - administration & dosage (8) 8
dideoxynucleosides - adverse effects (8) 8
dosage and administration (8) 8
health aspects (8) 8
lamivudine - administration & dosage (8) 8
lipids (8) 8
lopinavir/ritonavir (8) 8
medicine (8) 8
multidisciplinary sciences (8) 8
organophosphonates - adverse effects (8) 8
prevention (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2014, Volume 14, Issue 7, pp. 572 - 580
Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether dual... 
INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | SAFETY | ANALOGS | EFAVIRENZ | LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | SPARING REGIMEN | TENOFOVIR/EMTRICITABINE
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 2019, Volume 170, Issue 9, pp. 614 - 625
Background: Dolutegravir is superior to efavirenz for HIV antiretroviral therapy (ART) but may be associated with an increased risk for neural tube defects... 
VIRAL LOAD | MEDICINE, GENERAL & INTERNAL | COST-EFFECTIVENESS | TRANSMISSION | THERAPY | EFFICACY | ZIDOVUDINE | SAFETY | NAIVE | TENOFOVIR/EMTRICITABINE | COMBINATION
Journal Article
International Journal of STD & AIDS, ISSN 0956-4624, 4/2019, Volume 30, Issue 5, pp. 467 - 471
Raltegravir (RAL) is an HIV-1 integrase strand transfer inhibitor that is well established as a component of highly active antiretroviral therapy regimens for... 
human immunodeficiency virus | treatment | combination antiretroviral therapy | Antiretroviral therapy | viral disease | INFECTIOUS DISEASES | IMMUNOLOGY | TENOFOVIR/EMTRICITABINE
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 06/2017, Volume 75, Issue 2, pp. 226 - 231
In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs.... 
osteopenia | ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | ELVITEGRAVIR | proteinuria | COBICISTAT | EMTRICITABINE | IMMUNOLOGY | DENSITY | HIV | EFAVIRENZ | DOUBLE-BLIND | ABACAVIR/LAMIVUDINE | tenofovir alafenamide | TENOFOVIR/EMTRICITABINE
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 06/2017, Volume 75, Issue 2, pp. 211 - 218
In 2 double-blind phase 3 trials, 1733 antiretroviral-naive adults were randomized to tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), each... 
INFECTIOUS DISEASES | MULTICENTER | integrase inhibitor | RENAL-FUNCTION | ADULTS | OPEN-LABEL | PHASE-3 | IMMUNOLOGY | randomized controlled trial | NON-INFERIORITY | bone mineral density | renal safety | THERAPY | HIV | tenofovir alafenamide | INFECTED PATIENTS | TENOFOVIR/EMTRICITABINE
Journal Article
by Cahn, Pedro and Madero, Juan Sierra and Arribas, José Ramón and Antinori, Andrea and Ortiz, Roberto and Clarke, Amanda E and Hung, Chien-Ching and Rockstroh, Jürgen K and Girard, Pierre-Marie and Sievers, Jörg and Man, Choy and Currie, Alexander and Underwood, Mark and Tenorio, Allan R and Pappa, Keith and Wynne, Brian and Fettiplace, Anna and Gartland, Martin and Aboud, Michael and Smith, Kimberly and Cassetti, Lidia and David, Daniel and Figueras, Laura and Losso, Marcelo and Lopardo, Gustavo and Lupo, Sergio and Porteiro, Norma and Sánchez, Marisa and Bloch, Mark and Cooper, David and Finlayson, Robert and Kelleher, Anthony and Koh, Kenneth and Lewis, David and McMahon, James and Moore, Richard and Roth, Norman and Shields, Matthew and De Wit, Stephane and Florence, Eric and Goffard, Jean-Christophe and Demeester, Remy and Lacor, Patrick and Vandercam, Bernard and Vandekerckhove, Linos and Angel, Jonathan and Baril, Jean-Guy and Conway, Brian and De Pokomandy, Alexandra and Szabo, Jason and Walmsley, Sharon and Bouchaud, Olivier and Chidiac, Christian and Delobel, Pierre and Goujard, Cecile and Katlama, Christine and Molina, Jean-Michel and Pialoux, Gilles and Philibert, Patrick and Bogner, Johannes and Esser, Stefan and Krznaric, Ivanka and Lehmann, Clara and Spinner, Christoph and Stellbrink, Hans-Jurgen and Stephan, Christoph and Stoehr, Albrecht and Barchi, Enrico and Caramello, Pietro and Castelli, Francesco and Cattelan, Anna Maria and D'Arminio Monforte, Antonella and Di Biagio, Antonio and Di Perri, Giovanni and Gori, Andrea and Maggiolo, Franco and Menzaghi, Barbara and Migliorino, Guglielmo and Mussini, Cristina and Penco, Giovanni and Puoti, Massimo and Rizzardini, Giuliano and Gulminetti, Roberto and Lazzarin, Adriano and Quirino, Tiziano and Sighinolfi, Laura and Viale, Pierluigi and Amaya Tapia, Gerardo and Andrade Villanueva, Jaime and Granados Reyes, Enrique R and Perez Rios, Alma and Santoscoy Gomez, Mario and Den Hollander, Jan and Rijnders, Bart and Hidalgo, José A and Hercilla Vasquez, Luis and Illescas, Luis and Olczak, Anita and Mansinho, Kamal and Correia Pacheco, Patricia Paula and ... and GEMINI Study Team
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 143 - 155
Journal Article
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 11/2015, Volume 29, Issue 18, pp. 2459 - 2464
Objective:Antiretroviral therapy initiation has been linked to bone mineral density and bone biomarker changes. We assessed long-term bone turnover biomarker... 
POPULATION | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | RALTEGRAVIR | tenofovir | EMTRICITABINE | dolutegravir | IMMUNOLOGY | OSTEOPOROSIS | HIV-INFECTED PATIENTS | MINERAL DENSITY | VIROLOGY | bone markers | osteocalcin | FRACTURES | abacavir | TENOFOVIR/EMTRICITABINE | efavirenz
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 07/2018, Volume 67, Issue 3, pp. 411 - 419
Abstract Background Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has... 
tenofovir/emtricitabine | body composition | lipids | PrEP | lipodystrophy | INFECTIOUS DISEASES | WEIGHT CHANGE | MICROBIOLOGY | OPEN-LABEL | PHASE-3 | IMMUNOLOGY | HIV-INFECTED ADULTS | TRANSGENDER WOMEN | NON-INFERIORITY | ANTIRETROVIRAL PROPHYLAXIS | DOUBLE-BLIND | RANDOMIZED COMPARATIVE TRIAL | PLACEBO-CONTROLLED TRIAL | emtricitabine | tenofovir | and
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2011, Volume 204, Issue 8, pp. 1191 - 1201
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 49 - 57
Background: Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have... 
HIV-1 | Efficacy | Abacavir/lamivudine | Tenofovir/emtricitabine | Cardiovascular | Renal | ABACAVIR | tenofovir/emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | THYMIDINE ANALOG | TENOFOVIR DF | RISK | IMMUNOLOGY | cardiovascular | efficacy | abacavir/lamivudine | HIV-INFECTED PATIENTS | renal | REVERSE-TRANSCRIPTASE INHIBITORS | THERAPY | CHRONIC KIDNEY-DISEASE | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Glomerular Filtration Rate - drug effects | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | beta 2-Microglobulin - urine | Benzoxazines - adverse effects | Treatment Outcome | Retinol-Binding Proteins - urine | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations | Proteins | Antiretroviral drugs | Human immunodeficiency virus--HIV | Clinical trials | Adults | Drug therapy | Binding sites | Effectiveness studies
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 10/2017, Volume 76, Issue 2, pp. 177 - 182
Background: Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous... 
tenofovir/emtricitabine | INFECTIOUS DISEASES | pre-exposure prophylaxis | EMTRICITABINE/TENOFOVIR | DXA scan | PrEP | IMMUNOLOGY | TRANSGENDER WOMEN | TRIAL | bone mineral density | FRACTURE | ANTIRETROVIRAL PROPHYLAXIS | DISOPROXIL FUMARATE | MEN | DOUBLE-BLIND | INFECTION | EXPOSURE
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2015, Volume 61, Issue 3, pp. 403 - 408
Journal Article